Eli Lilly acquires ImClone Systems oncology franchise
1 report, 1 independent
Updated 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly and Company acquired ImClone Systems, integrating its oncology franchise. This acquisition is cited as a key historical entry point for Eli Lilly stock during the financial crisis.
From aol.com
Why it matters
The acquisition is highlighted as one of the best entry points for Eli Lilly stock, generating a 5,744% return for a $1,000 investment during the 2008 financial crisis. This return significantly surpassed the returns achieved from later approvals like Mounjaro and Zepbound.
From aol.com
Who's involved
- ImClone SystemsCompany whose oncology franchise was acquired by Eli Lilly and Company.
- Eli Lilly and CompanyAmerican pharmaceutical company that acquired the ImClone Systems oncology franchise.
Keep exploring
The entities involved
-
ImClone Systems
company
-
Eli Lilly and Company
American pharmaceutical company